Polyclonal Adaptive Regulatory CD4 Cells That Can Reverse Type I Diabetes Become Oligoclonal Long-term Protective Memory Cells

Overview

Journal J Immunol

Specialty Allergy & Immunology

Date 2008 Jul 22

PMID 18641317

Citations 26

Authors

Elana Godebu

Daphne Summers-Torres

Melissa M Lin

Bas J G Baaten

Linda M Bradley

Affiliations

Soon will be listed here.

Abstract

Type 1 diabetes is a CD4 cell-dependent disease that results from destruction of insulin-producing beta cells in pancreatic islets. An ideal therapy would reverse diabetes shortly after onset when islet function in not yet fully ablated, and also prevent re-emergence of disease through the generation of memory cells that control the autoimmune response. In this study, we show that adaptive/induced polyclonal regulatory (TR) cells, which contain islet-reactive cells, fulfill these criteria in the NOD mouse model. CD4 cells induced to express FoxP3, IL-10, and TGF-beta1 in response to TCR signaling and TGF-beta1 can reverse diabetes with clinical restoration of prediabetic serum levels of IL-10. Unlike naturally occurring TR cells, these adaptive TR cells persist indefinitely (>1 year) as FoxP3(+), CD25(-) memory cells that self-renew. Establishment of memory is accompanied by narrowing of the T cell repertoire to usage of a single TCR beta-chain, Vbeta11, implying selection by Ag. With islet-specific adaptive TR cells, we show that memory is functionally stable and transferable. Therefore, adaptive TR cells, which can be readily generated from normal CD4 populations and become focused by Ag with induction of memory, may provide a treatment and a vaccine for the long-term cure of diabetes making them attractive as immunotherapeutic agents.

Citing Articles

Neuropilin-1 Identifies a New Subpopulation of TGF-β-Induced Foxp3 Regulatory T Cells With Potent Suppressive Function and Enhanced Stability During Inflammation.

Chen W, Huang W, Xue Y, Chen Y, Qian W, Ma J Front Immunol. 2022; 13:900139.

PMID: 35603221 PMC: 9114772. DOI: 10.3389/fimmu.2022.900139.

Cryptotanshinone possesses therapeutic effects on ischaemic stroke through regulating STAT5 in a rat model.

Zhu F, Chen H, Xu M, Zhang X, Yu J, Pan Y Pharm Biol. 2021; 59(1):465-471.

PMID: 33915069 PMC: 8871624. DOI: 10.1080/13880209.2021.1914672.

Adoptive Cell Therapy of Induced Regulatory T Cells Expanded by Tolerogenic Dendritic Cells on Murine Autoimmune Arthritis.

Yang J, Liu L, Yang Y, Kong N, Jiang X, Sun J J Immunol Res. 2017; 2017:7573154.

PMID: 28702462 PMC: 5494067. DOI: 10.1155/2017/7573154.

Next-Generation Sequencing Reveals Restriction and Clonotypic Expansion of Treg Cells in Juvenile Idiopathic Arthritis.

Henderson L, Volpi S, Frugoni F, Janssen E, Kim S, Sundel R Arthritis Rheumatol. 2016; 68(7):1758-68.

PMID: 26815131 PMC: 5398095. DOI: 10.1002/art.39606.

Combination Therapy Reverses Hyperglycemia in NOD Mice With Established Type 1 Diabetes.

Xue S, Posgai A, Wasserfall C, Myhr C, Campbell-Thompson M, Mathews C Diabetes. 2015; 64(11):3873-84.

PMID: 26185279 PMC: 4613966. DOI: 10.2337/db15-0164.

References

Fantini M, Becker C, Monteleone G, Pallone F, Galle P, Neurath M . Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol. 2004; 172(9):5149-53. DOI: 10.4049/jimmunol.172.9.5149. View

Horwitz D, Zheng S, Gray J, Wang J, Ohtsuka K, Yamagiwa S . Regulatory T cells generated ex vivo as an approach for the therapy of autoimmune disease. Semin Immunol. 2004; 16(2):135-43. DOI: 10.1016/j.smim.2003.12.009. View

Malek T, Yu A, Vincek V, Scibelli P, Kong L . CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity. 2002; 17(2):167-78. DOI: 10.1016/s1074-7613(02)00367-9. View

Setoguchi R, Hori S, Takahashi T, Sakaguchi S . Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med. 2005; 201(5):723-35. PMC: 2212841. DOI: 10.1084/jem.20041982. View

Jaeckel E, Kretschmer K, Apostolou I, von Boehmer H . Instruction of Treg commitment in peripheral T cells is suited to reverse autoimmunity. Semin Immunol. 2006; 18(2):89-92. DOI: 10.1016/j.smim.2006.01.011. View

Weber S, Harbertson J, Godebu E, Mros G, Padrick R, Carson B . Adaptive islet-specific regulatory CD4 T cells control autoimmune diabetes and mediate the disappearance of pathogenic Th1 cells in vivo. J Immunol. 2006; 176(8):4730-9. DOI: 10.4049/jimmunol.176.8.4730. View

Judkowski V, Pinilla C, Schroder K, Tucker L, Sarvetnick N, Wilson D . Identification of MHC class II-restricted peptide ligands, including a glutamic acid decarboxylase 65 sequence, that stimulate diabetogenic T cells from transgenic BDC2.5 nonobese diabetic mice. J Immunol. 2001; 166(2):908-17. DOI: 10.4049/jimmunol.166.2.908. View

Chen Y, Kuchroo V, Inobe J, Hafler D, Weiner H . Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science. 1994; 265(5176):1237-40. DOI: 10.1126/science.7520605. View

Prussin C, Metcalfe D . Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. J Immunol Methods. 1995; 188(1):117-28. DOI: 10.1016/0022-1759(95)00209-x. View

10.

von Boehmer H . Mechanisms of suppression by suppressor T cells. Nat Immunol. 2005; 6(4):338-44. DOI: 10.1038/ni1180. View

11.

Collison L, Workman C, Kuo T, Boyd K, Wang Y, Vignali K . The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007; 450(7169):566-9. DOI: 10.1038/nature06306. View

12.

Linton P, Bautista B, Biederman E, Bradley E, Harbertson J, Kondrack R . Costimulation via OX40L expressed by B cells is sufficient to determine the extent of primary CD4 cell expansion and Th2 cytokine secretion in vivo. J Exp Med. 2003; 197(7):875-83. PMC: 2193894. DOI: 10.1084/jem.20021290. View

13.

You S, Leforban B, Garcia C, Bach J, Bluestone J, Chatenoud L . Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci U S A. 2007; 104(15):6335-40. PMC: 1851030. DOI: 10.1073/pnas.0701171104. View

14.

Katz J, Wang B, Haskins K, Benoist C, Mathis D . Following a diabetogenic T cell from genesis through pathogenesis. Cell. 1993; 74(6):1089-100. DOI: 10.1016/0092-8674(93)90730-e. View

15.

Kondrack R, Harbertson J, Tan J, McBreen M, Surh C, Bradley L . Interleukin 7 regulates the survival and generation of memory CD4 cells. J Exp Med. 2003; 198(12):1797-806. PMC: 2194153. DOI: 10.1084/jem.20030735. View

16.

Haverkos H, Battula N, Drotman D, Rennert O . Enteroviruses and type 1 diabetes mellitus. Biomed Pharmacother. 2003; 57(9):379-85. DOI: 10.1016/j.biopha.2003.03.001. View

17.

Tang Q, Henriksen K, Bi M, Finger E, Szot G, Ye J . In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004; 199(11):1455-65. PMC: 2211775. DOI: 10.1084/jem.20040139. View

18.

Apostolou I, Sarukhan A, Klein L, von Boehmer H . Origin of regulatory T cells with known specificity for antigen. Nat Immunol. 2002; 3(8):756-63. DOI: 10.1038/ni816. View

19.

Garin M, Chu C, Golshayan D, Cernuda-Morollon E, Wait R, Lechler R . Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood. 2006; 109(5):2058-65. DOI: 10.1182/blood-2006-04-016451. View

20.

Tarbell K, Yamazaki S, Olson K, Toy P, Steinman R . CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med. 2004; 199(11):1467-77. PMC: 2211787. DOI: 10.1084/jem.20040180. View